Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date

Nowadays the therapeutic landscape for advanced and metastatic urothelial carcinoma continues to evolve. The recent regulatory approval of enfortumab vedotin (EV) for the treatment of advanced urothelial cancer confirms the evolving role of antibody-drug conjugates. EV demonstrates a favorable profi...

Descripción completa

Detalles Bibliográficos
Autores principales: Moussa, Mohamad, Papatsoris, Athanasios, Abou Chakra, Mohamed, Dellis, Athanasios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886109/
https://www.ncbi.nlm.nih.gov/pubmed/33603337
http://dx.doi.org/10.2147/DDDT.S240854

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886109/
https://www.ncbi.nlm.nih.gov/pubmed/33603337
http://dx.doi.org/10.2147/DDDT.S240854

Ejemplares similares